2-methyl-2-(2-nitro-4-methylphenoxy)propanal | 130205-08-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-methyl-2-(2-nitro-4-methylphenoxy)propanal
• 英文别名: 2-(4-methyl-2-nitrophenoxy)-2-methylpropanal；2-methyl-2-(4-methyl-2-nitrophenoxy)propanal
• CAS: 130205-08-2
• 化学式: C₁₁H₁₃NO₄
• 分子量: 223.229
• InChiKey: FNNXLWQFXUNRKE-UHFFFAOYSA-N

物化性质

• 沸点：
  359.8±27.0 °C(Predicted)
• 密度：
  1.184±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-methyl-2-(2-nitro-4-methylphenoxy)propanal 、 4(Z)-6-cis-<2,2-dimethyl-4-(3-pyridyl)-1,3-dioxan-5-yl>hexenoic acid 在 对甲苯磺酸 作用下， 以 乙腈 为溶剂， 反应 5.0h， 以28%的产率得到(Z)-6-{(2R,4R,5S)-2-[1-Methyl-1-(4-methyl-2-nitro-phenoxy)-ethyl]-4-pyridin-3-yl-[1,3]dioxan-5-yl}-hex-4-enoic acid
  参考文献：
  名称：

  Dual-Acting Thromboxane Receptor Antagonist/Synthase Inhibitors: Synthesis and Biological Properties of [2-Substituted-4-(3-pyridyl)-1,3-dioxan-5-yl]alkenoic Acids

  摘要：

  The design, synthesis, and pharmacology of a new class of compounds possessing both thromboxane receptor antagonist and thromboxane synthase inhibitory properties are described. Replacement of the phenol group of the known thromboxane antagonist series 4(Z)-6-[(4RS,5SR)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]hex-4-enoic acid by a 3-pyridyl group led to a series of compounds, 5, which were potent thromboxane synthase inhibitors and weak thromboxane antagonists. Further modifications at the dioxane C2 position led to compounds, 7, which were potent dual-acting agents. In the case of compound 7w, the dual activity was shown to reside almost exclusively in the (-)-enantiomer, 7x. Following oral dosing to rats and dogs, 7x (3 mg/kg) displayed significant dual activity over a period of at least 8 h.

  DOI：

  10.1021/jm00004a014
• 作为产物：
  描述：

  2-溴-2-甲基丙醛 、 2-硝基-4-甲苯酚 在 sodium hydride 作用下， 生成 2-methyl-2-(2-nitro-4-methylphenoxy)propanal
  参考文献：
  名称：

  Dual-Acting Thromboxane Receptor Antagonist/Synthase Inhibitors: Synthesis and Biological Properties of [2-Substituted-4-(3-pyridyl)-1,3-dioxan-5-yl]alkenoic Acids

  摘要：

  The design, synthesis, and pharmacology of a new class of compounds possessing both thromboxane receptor antagonist and thromboxane synthase inhibitory properties are described. Replacement of the phenol group of the known thromboxane antagonist series 4(Z)-6-[(4RS,5SR)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]hex-4-enoic acid by a 3-pyridyl group led to a series of compounds, 5, which were potent thromboxane synthase inhibitors and weak thromboxane antagonists. Further modifications at the dioxane C2 position led to compounds, 7, which were potent dual-acting agents. In the case of compound 7w, the dual activity was shown to reside almost exclusively in the (-)-enantiomer, 7x. Following oral dosing to rats and dogs, 7x (3 mg/kg) displayed significant dual activity over a period of at least 8 h.

  DOI：

  10.1021/jm00004a014

文献信息

• Pyridine derivatives
  申请人：Imperial Chemical Industries PLC

  公开号：US05053415A1

  公开（公告）日：1991-10-01

  The invention concerns novel, pharmaceutically useful 1,3-dioxane alkenoic acid derivatives of the formula I containing a pyridyl moiety at position 4 of the dioxane ring and in which the groups at positions 2, 4 and 5 have cis-relative stereochemistry, X is hydrogen, alkoxy or hydroxy, Y is vinylene, n is 1 or 2, A.sup.1 is alkylene, the substituents R.sup.1 and R.sup.2 at position 2 of the dioxane ring have a variety of values defined hereinafter, and R.sup.4 is hydroxy, a physiologically acceptable alcohol residue or alkanesulphonamido, and the pharmaceutically acceptable salts thereof. The invention also includes processes for the manufacture and use of the acid derivatives as well as pharmaceutical compositions for therapeutic use in one or more of a variety of diseases such as ischaemic heart disease, cerebrovascular disease, asthmatic disease and/or inflammatory disease.

  本发明涉及一类新型的、具有药物活性的1,3-二氧杂环戊烷烯酸衍生物，其通式为I，其中二氧杂环戊烷环的第4位含有吡啶基团，且第2、4和5位的基团具有顺式相对立体化学结构，X是氢、烷氧基或羟基，Y是乙烯基，n是1或2，A.sup.1是亚烷基，二氧杂环戊烷环第2位的取代基R.sup.1和R.sup.2具有多种后续定义的值，而R.sup.4是羟基、生理上可接受的醇残基或烷磺酰胺基，以及它们的药物可接受盐。本发明还包括制造和使用这些酸衍生物的方法，以及用于治疗多种疾病如缺血性心脏病、脑血管病、哮喘病和/或炎症性疾病的药物组合物。
• Heterocyclic acids
  申请人：ZENECA LIMITED

  公开号：EP0482771B1

  公开（公告）日：1997-06-18
• US5053415A
  申请人：——

  公开号：US5053415A

  公开（公告）日：1991-10-01
• US5219874A
  申请人：——

  公开号：US5219874A

  公开（公告）日：1993-06-15
• US5410064A
  申请人：——

  公开号：US5410064A

  公开（公告）日：1995-04-25